http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2345996-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90d4c9eb6f4837513dd1a4c6906f811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b98606d9cda02a2861481483e9fe4b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 |
| filingDate | 2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b96b301ef1181826f475c92a2f07284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d404b8e14c73c94ed625a68e6dcff823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6d0f6291da5ee4b11c67a1e4a5da18e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9d6475b65e0a12129b2f9e53a50c016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8de4d6b33b77e36a6759f017362522e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac8c0c477021feabdc0296fe00d81120 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7399850d24a538f75d6bb80bad34606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a5c695e75ca9798b951a67abc097f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9687459d5c7fb34297c8d3edeb05e95 |
| publicationDate | 2009-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2345996-C1 |
| titleOfInvention | Annelated azaheterocyclic amides, which include pyrimidine fragment, method of obtaining and their application |
| abstract | FIELD: chemistry. n SUBSTANCE: present invention relates to new annelated azaheterocyclic amides, including a pyrimidine fragment, with the general formula 1, method of obtaining them and their application in the form of free bases or their pharmaceutically accepted salts as inhibitors of P13K kinase, in compounds with the general formula 1: , where: X represents an oxygen atom, sulphur atom or not necessarily substituted at the nitrogen NH group, where the substitute is selected from lower alkyls and possibly a substituted aryl; Y represents an atom of nitrogen or substituted at the carbon atom CH group, where the substitute is selected from lower alkyls; Z represents an oxygen atom; R1 represents a hydrogen atom or not necessarily substituted C 1 -C 6 alkyl, or Z represents a nitrogen atom, which is together with a carbon atom, with which it is joined, form through Z and R1 annelated imidazole cycle; R2 and R3 independently from each other represent hydrogen, not necessarily substituted with C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, not necessarily substituted with phenyl, not necessarily substituted with 6-member aza-heteroaryl, under the condition, when Y represents a nitrogen atom, or R2 and R3 independently from each other represent not necessarily substituted C 1 -C 6 alkyl, not necessarily substituted with phenyl, not necessarily substituted with 5-7-member heterocycle with 1-2 heteroatoms, selected from nitrogen and oxygen, and possibly annelated with a phenyl ring, under the condition, when Y does not necessarily represent a substituted carbon atom at the CH group, and X represents an oxygen atom, sulphur atom, or R2 represents hydrogen, and R3 represents a substituted aminoC 1 -C 6 alkyl and not necessarily substituted 5-6-member aza-heterocycloalkyl, under the condition, when Y represents a group which is substituted at the CH atom, and X represents an oxygen atom, sulphur atom, or R2 represents hydrogen, and R3 represents phenyl which is not necessarily substituted, pyridyl which is not necessarily substituted, pyrimidinyl which is not necessarily substituted, under the conditions, when R1 represents a substituted aminoC 1 -C 6 alkyl, substituted C 2 -C 3 hydroxyalkyl and aza-heterocycloalkyl not necessarily substituted, Y represents a group with CH substituted, and X represents an oxygen atom, sulphur, and the substitute of the above indicated substituted alkyl, phenyl, heterocycle, pyridyl, pyrimidyl are selected from groups of hydroxyl-, cyano-groups, hydrogen, lower alkyls, possibly mono- or di-substituted lower alkyl sulfamoyl, carbamoyl, C 1 -C 6 alkoxycarbonyl, amino, mono- or di-lower alkyl-amine, N-(lower alkyl), N-(phenylC 1 -C 6 alkyl)amine, phenyl, possibly substituted with a halogen atom, C 1 -C 6 alkyl, haloid-C 1 -C 6 alkyl; phenylC 1 -C 6 alkyl, saturated or non-saturated 5-6-member heterocycle containing 1-2-heteroatoms, selected from nitrogen, oxygen and sulphur, and possible condensation with a benzene ring R4 represents hydrogen or a lower alkyl. n EFFECT: obtaining new annelated aza-heterocyclic amides, including a pyrimidine fragment, with the general formula with the possibility of their application in the form of free bases or their pharmaceutically accepted salts as inhibitors of PI3K kinase. n 16 cl, 5 tbl, 5 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2557237-C2 |
| priorityDate | 2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.